MYC rs6985725: What Your Genotype Means
The rs6985725 variant is a common genetic change located in a gene desert near the MYC oncogene. It has been statistically associated with an increased risk of developing certain types of cancer, including colorectal and prostate cancers.
What each genotype means
Baseline risk profile
This genotype represents the homozygous state for the major allele at this location. Research indicates this variant is located in a gene desert near the MYC oncogene and has been associated with variations in cancer risk, though the clinical significance for an individual remains limited. This finding should not be used to predict personal health outcomes or diagnose disease.
This is a common genotype, occurring in approximately 25-30% of individuals of European ancestry.
Increased risk association
This heterozygous genotype includes one copy of the allele associated with increased risk in some population-based studies of colorectal and prostate cancers. Because this variant is located in a non-coding region near the MYC gene, its exact biological mechanism is still being investigated. Please discuss any concerns regarding cancer screening or family history with your healthcare provider.
This genotype is found in roughly 45-50% of individuals of European ancestry.
Elevated risk association
This homozygous genotype carries two copies of the allele associated with higher statistical risk for certain cancers in large-scale association studies. While this association is documented in the literature, it is a complex trait influenced by many other genetic and environmental factors. This result is not a medical diagnosis and should be discussed in the context of your overall health with a clinician.
This genotype is observed in approximately 20-25% of individuals of European ancestry.
Understanding the rs6985725 Variant
The rs6985725 variant is a single nucleotide polymorphism, or SNP, which is a variation at a single position in the DNA sequence. This specific variant is located in a region of the genome often described as a gene desert, meaning it sits in a large stretch of DNA that does not contain protein-coding genes. Despite its location outside of a gene, researchers have identified this site as a region of interest because it is situated near the MYC gene. In genetic studies, variants in non-coding regions are frequently investigated for their potential role in regulating the expression of nearby genes. While the variant itself does not change the structure of a protein, it may influence how the MYC gene is turned on or off in different tissues, which is a subject of ongoing scientific inquiry.
The Role of the MYC Gene
The MYC gene is a well-known oncogene, which is a type of gene that, when mutated or expressed at abnormal levels, has the potential to cause normal cells to become cancerous. MYC encodes a transcription factor that plays a critical role in many essential cellular processes, including cell cycle progression, apoptosis, and cellular transformation. Because of its central role in controlling cell growth and division, the activity of MYC is tightly regulated in healthy cells. When this regulation is disrupted, it can lead to uncontrolled cell proliferation. Research into the relationship between rs6985725 and MYC often focuses on whether this variant acts as an enhancer or a regulatory element that might alter the levels of MYC protein, thereby contributing to the complex biological pathways that influence cancer development.
Research Associations and Evidence Strength
The association between rs6985725 and cancer risk has been identified through genome-wide association studies (GWAS). These studies look for correlations between specific genetic variants and health traits across large populations. The evidence linking rs6985725 to an increased risk of colorectal and prostate cancers is currently considered limited. In the context of genetic research, a limited evidence strength means that while statistical associations have been observed, the biological mechanism is not fully understood, and the effect size of the variant on individual risk is generally small. It is important to note that having this variant does not mean an individual will develop cancer. Cancer is a multifactorial disease influenced by a combination of genetics, lifestyle factors, and environmental exposures, and this variant represents only one small piece of a much larger, complex puzzle.
Population Frequency
The rs6985725 variant is considered a common genetic polymorphism. In European populations, the frequency of this variant is approximately 45% to 50%. Because it is so common, a large portion of the general population carries at least one copy of the variant. Genetic frequency can vary significantly across different ancestral groups, and researchers use databases like gnomAD to track these differences. Understanding the prevalence of a variant helps scientists determine if an association is consistent across diverse groups or if it is specific to certain populations. Given its high frequency, the variant is widely distributed, which underscores the importance of viewing such genetic findings in the context of overall population health rather than as a diagnostic tool for individuals.
What This Information Means for You
If you have learned that you carry the rs6985725 variant, it is helpful to understand that this is a common finding and not a medical diagnosis. Genetic variants identified in GWAS are used by researchers to understand biological pathways and disease susceptibility at a population level, not to predict individual health outcomes. You cannot use this information to determine your personal risk of cancer or to make medical decisions. If you have concerns about your family history of cancer or your personal health, the most appropriate step is to consult with a healthcare professional or a genetic counselor. They can provide context based on your full medical history and help you understand what screening or preventative measures might be appropriate for your specific situation.
How common is this variant?
The rs6985725 variant is common, with an allele frequency of approximately 45-50% in European populations.
Frequently asked questions
Does having the rs6985725 variant mean I will get cancer?
No. This variant is associated with a small change in statistical risk at a population level, not an individual diagnosis. Most people who carry this variant will never develop cancer.
Should I get tested for this variant?
Genetic testing for common variants like rs6985725 is generally not recommended for clinical purposes. These variants do not provide enough information to guide personal medical care.
How does a variant in a 'gene desert' affect my health?
Variants in gene deserts may influence how nearby genes are regulated. Scientists study these regions to understand how DNA sequences outside of genes can still impact biological processes.
What should I do if I am worried about my cancer risk?
If you are concerned about cancer risk, speak with your doctor. They can evaluate your personal and family history to determine if screening or genetic counseling is appropriate for you.
Sources & further reading
Educational information only, last refreshed 9/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6985725?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MYC
This variant in the 8q24 region is associated with increased prostate cancer risk in men of West African and Puerto Rican ancestry.
This variant is a well-established risk factor for colorectal and prostate cancer susceptibility.
Non-coding variant in the 8q24 region near MYC associated with increased risk of colorectal and prostate cancers.
This non-coding variant on chromosome 8q24 near the MYC proto-oncogene is significantly associated with an increased susceptibility to bladder cancer.
An intergenic variant at 7q31.1 demonstrated to associate with physician-diagnosed allergic conditions including allergic rhinitis.